Enviromed
Article Abstract:
Enviromed is a supplier of diagnostic enzymes, and has a subsidiary, Biozyme, with an 8% stake in the global market, though a turnover of under 6 million pounds sterling. Enviromed has reached an agreement with Selfcare and with preference stockholders, to whom it has to make payments. The company's debt dropped to some 1.8 million pounds sterling in Sep 1999, excluding preference stocks. The company's profit is estimated at 1.4 million pounds sterling for Sep 1998 to Sep 1999, and could rise to 1.7 million pounds for 1999-2000.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Amersham
Article Abstract:
Amersham has made a cross-licensing agreement with Roche Molecular Systems and Perkin Elmer Applied Biosystems. The company will provide patent access to enzymes it has developed for sequencing, a market which is growing rapidly. The company has also set up a successful JV with Sumitomo Medical Corp called Nihon Medi-Physics (NMP) which is performing better than expected. The company's Japanese healthcare operations have been merged with NMP and Amersham ranks first in the world market for nuclear medicine.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Amersham
Article Abstract:
Amersham has seen a strong performance from its healthcare division, but its life science division has performed less well. The company saw a 43% rise in sales of its pain reliever, Metastron, but life sciences have been hit by pressure on funding for academic research. Price competition has hit European operations. The company has acquired a 20% stake in Nihon MediPhysics with an option to increase this to 50%, which would give the company leadership in the world market.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
User Contributions:
Comment about this article or add new information about this topic: